Barely Significant
← all excerpts

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.

Ann Oncol · 2017 · PMC5391716 · PMID 28039180

Europe PMCDOI
1
hedged sentence
0.0090
closest p · 0.2× alpha
0.0090
boldest claim

The sentences

highly significantP = 0.009actually significant
The maximum benefit in the CROSS-trial was observed in squamous cell carcinoma, with highly significant (HR = 0.48; 95%C.I. 0.28–0.83; P = 0.009) benefit compared with surgery alone, in comparison with adenocarcinoma, where the benefit was more modest (HR = 0.73; 95%C.I.0.55–0.98; P = 0.037), but the benefit of neoadjuvant chemoradiotherapy was consistent across subgroups, without any significant interaction identified [ 1 , 2 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.